NKBP Share Price

Open 5.71 Change Price %
High 5.71 1 Day -0.12 -2.12
Low 5.54 1 Week 0.00 0.00
Close 5.54 1 Month 0.00 0.00
Volume 6302 1 Year 0.00 0.00
52 Week High 41.39
52 Week Low 0.00
NKBP Important Levels
Resistance 2 5.70
Resistance 1 5.63
Pivot 5.60
Support 1 5.45
Support 2 5.38
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
WRES 0.09 0.00%
SIRI 4.41 1.85%
QQQ 116.87 0.23%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ECTE 0.14 40.00%
BNSO 3.57 31.25%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
CRDS 5.45 25.87%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
IMRS 0.02 -33.33%
More..

China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP)

NKBP Technical Analysis 2
As on 6th Feb 2013 NKBP Share Price closed @ 5.54 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 4.76 & Sell for SHORT-TERM with Stoploss of 5.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
NKBP Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
NKBP Other Details
Segment EQ
Market Capital 107240808.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
NKBP Address
NKBP
N/A
NKBP Latest News
Renren Inc. Announces Appointment of Two New Independent Directors   Yahoo Finance   - 05th Dec 16
Zhaopin Announces Appointment of New Chief Financial Officer   PR Newswire (press release)   - 25th Jan 16
A Legal Overview Of M&A In The Cayman Islands And British Virgin Islands   Mondaq News Alerts (registration)   - 30th Apr 14
China Nuokang Bio Pharmaceutical Inc Announces Completion Of Merger   Reuters Key Development   - 07th Feb 13
China Nuokang Bio-Pharmaceutical Inc. Announces Completion of Merger   GlobeNewswire (press release)   - 07th Feb 13
What's the Best Chinese Pharma or Biotech Stock?   SmallCap Network   - 16th Jan 13
Forbes China's Top Venture Capitalists   Forbes (blog)   - 29th Apr 11
Vipshop Raises $20 Million in Series A Funding   Business Wire (press release)   - 08th Nov 10
UQ biotech company climbs the ladder for snake venom-research   UQ News   - 28th Sep 09
Interactive Technical Analysis Chart China Nuokang Bio-Pharmaceutical Inc. ( NKBP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on China Nuokang Bio-Pharmaceutical Inc.
NKBP Business Profile
China Nuokang Bio-Pharmaceutical Inc. is a biopharmaceutical company focused on research, development, manufacture, marketing and sales of hospital-based medical products. As of December 31, 2010, it sold a portfolio of 15 products, including four principal products: Baquting, its bleeding control product; Kaitong, its lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; Aiduo, its cardiovascular stress imaging agent, and Aiwen, its anti-arrhythmic agent. Its product pipeline includes three product candidates under development for bleeding control and hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. In February 2013, it announced the completion of the merger with Kingbird Mergerco. Inc., a wholly owned subsidiary of Kingbird Investment Inc. As a result of the merger the Company became a wholly owned subsidiary of Kingbird Investment Inc.